Intrinsic value of Neogen - NEOG

Previous Close

$63.12

  Intrinsic Value

$13.33

stock screener

  Rating & Target

str. sell

-79%

Previous close

$63.12

 
Intrinsic value

$13.33

 
Up/down potential

-79%

 
Rating

str. sell

We calculate the intrinsic value of NEOG stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 3.3

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  10.60
  10.04
  9.54
  9.08
  8.67
  8.31
  7.98
  7.68
  7.41
  7.17
  6.95
  6.76
  6.58
  6.42
  6.28
  6.15
  6.04
  5.93
  5.84
  5.76
  5.68
  5.61
  5.55
  5.50
  5.45
  5.40
  5.36
  5.33
  5.29
  5.26
Revenue, $m
  445
  490
  536
  585
  636
  688
  743
  800
  860
  921
  986
  1,052
  1,121
  1,193
  1,268
  1,346
  1,428
  1,512
  1,601
  1,693
  1,789
  1,889
  1,994
  2,104
  2,219
  2,338
  2,464
  2,595
  2,732
  2,876
Variable operating expenses, $m
  364
  399
  435
  474
  513
  555
  598
  643
  689
  738
  773
  826
  880
  936
  995
  1,056
  1,120
  1,187
  1,256
  1,328
  1,404
  1,483
  1,565
  1,651
  1,741
  1,835
  1,933
  2,036
  2,144
  2,257
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  364
  399
  435
  474
  513
  555
  598
  643
  689
  738
  773
  826
  880
  936
  995
  1,056
  1,120
  1,187
  1,256
  1,328
  1,404
  1,483
  1,565
  1,651
  1,741
  1,835
  1,933
  2,036
  2,144
  2,257
Operating income, $m
  81
  91
  101
  111
  122
  134
  145
  158
  171
  184
  212
  227
  242
  257
  273
  290
  307
  326
  345
  365
  385
  407
  430
  453
  478
  504
  531
  559
  588
  619
EBITDA, $m
  108
  119
  130
  142
  155
  167
  181
  195
  209
  224
  240
  256
  273
  290
  308
  327
  347
  368
  389
  412
  435
  459
  485
  512
  539
  568
  599
  631
  664
  699
Interest expense (income), $m
  0
  0
  0
  1
  1
  1
  2
  2
  3
  3
  4
  4
  5
  5
  6
  6
  7
  7
  8
  9
  9
  10
  11
  12
  12
  13
  14
  15
  16
  17
  18
Earnings before tax, $m
  81
  90
  100
  110
  121
  132
  143
  155
  167
  180
  208
  222
  236
  251
  267
  283
  300
  318
  336
  355
  375
  396
  418
  441
  465
  490
  516
  543
  571
  601
Tax expense, $m
  22
  24
  27
  30
  33
  36
  39
  42
  45
  49
  56
  60
  64
  68
  72
  76
  81
  86
  91
  96
  101
  107
  113
  119
  125
  132
  139
  147
  154
  162
Net income, $m
  59
  66
  73
  81
  88
  96
  105
  113
  122
  132
  152
  162
  173
  184
  195
  207
  219
  232
  245
  259
  274
  289
  305
  322
  339
  357
  376
  396
  417
  439

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  493
  543
  595
  648
  705
  763
  824
  887
  953
  1,022
  1,093
  1,166
  1,243
  1,323
  1,406
  1,493
  1,583
  1,677
  1,775
  1,877
  1,983
  2,095
  2,211
  2,333
  2,460
  2,592
  2,731
  2,877
  3,029
  3,189
Adjusted assets (=assets-cash), $m
  493
  543
  595
  648
  705
  763
  824
  887
  953
  1,022
  1,093
  1,166
  1,243
  1,323
  1,406
  1,493
  1,583
  1,677
  1,775
  1,877
  1,983
  2,095
  2,211
  2,333
  2,460
  2,592
  2,731
  2,877
  3,029
  3,189
Revenue / Adjusted assets
  0.903
  0.902
  0.901
  0.903
  0.902
  0.902
  0.902
  0.902
  0.902
  0.901
  0.902
  0.902
  0.902
  0.902
  0.902
  0.902
  0.902
  0.902
  0.902
  0.902
  0.902
  0.902
  0.902
  0.902
  0.902
  0.902
  0.902
  0.902
  0.902
  0.902
Average production assets, $m
  158
  174
  190
  208
  226
  244
  264
  284
  305
  327
  350
  373
  398
  424
  450
  478
  507
  537
  568
  601
  635
  671
  708
  747
  788
  830
  875
  921
  970
  1,021
Working capital, $m
  140
  154
  168
  184
  200
  216
  233
  251
  270
  289
  309
  330
  352
  375
  398
  423
  448
  475
  503
  532
  562
  593
  626
  661
  697
  734
  774
  815
  858
  903
Total debt, $m
  6
  13
  19
  26
  34
  41
  49
  58
  66
  75
  84
  94
  104
  114
  125
  136
  148
  160
  173
  186
  200
  214
  230
  245
  262
  279
  297
  316
  336
  357
Total liabilities, $m
  64
  71
  77
  84
  92
  99
  107
  115
  124
  133
  142
  152
  162
  172
  183
  194
  206
  218
  231
  244
  258
  272
  287
  303
  320
  337
  355
  374
  394
  415
Total equity, $m
  429
  472
  517
  564
  613
  664
  717
  772
  829
  889
  951
  1,015
  1,082
  1,151
  1,223
  1,299
  1,377
  1,459
  1,544
  1,633
  1,726
  1,822
  1,924
  2,029
  2,140
  2,255
  2,376
  2,503
  2,635
  2,774
Total liabilities and equity, $m
  493
  543
  594
  648
  705
  763
  824
  887
  953
  1,022
  1,093
  1,167
  1,244
  1,323
  1,406
  1,493
  1,583
  1,677
  1,775
  1,877
  1,984
  2,094
  2,211
  2,332
  2,460
  2,592
  2,731
  2,877
  3,029
  3,189
Debt-to-equity ratio
  0.010
  0.030
  0.040
  0.050
  0.060
  0.060
  0.070
  0.070
  0.080
  0.080
  0.090
  0.090
  0.100
  0.100
  0.100
  0.100
  0.110
  0.110
  0.110
  0.110
  0.120
  0.120
  0.120
  0.120
  0.120
  0.120
  0.130
  0.130
  0.130
  0.130
Adjusted equity ratio
  0.870
  0.870
  0.870
  0.870
  0.870
  0.870
  0.870
  0.870
  0.870
  0.870
  0.870
  0.870
  0.870
  0.870
  0.870
  0.870
  0.870
  0.870
  0.870
  0.870
  0.870
  0.870
  0.870
  0.870
  0.870
  0.870
  0.870
  0.870
  0.870
  0.870

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  59
  66
  73
  81
  88
  96
  105
  113
  122
  132
  152
  162
  173
  184
  195
  207
  219
  232
  245
  259
  274
  289
  305
  322
  339
  357
  376
  396
  417
  439
Depreciation, amort., depletion, $m
  27
  28
  30
  31
  32
  34
  35
  37
  38
  40
  27
  29
  31
  33
  35
  37
  40
  42
  44
  47
  50
  52
  55
  58
  62
  65
  68
  72
  76
  80
Funds from operations, $m
  86
  94
  103
  111
  120
  130
  140
  150
  161
  172
  179
  191
  204
  217
  230
  244
  259
  274
  290
  306
  324
  342
  360
  380
  401
  422
  445
  468
  493
  519
Change in working capital, $m
  13
  14
  15
  15
  16
  17
  17
  18
  19
  19
  20
  21
  22
  23
  24
  25
  26
  27
  28
  29
  30
  32
  33
  34
  36
  38
  39
  41
  43
  45
Cash from operations, $m
  73
  80
  88
  96
  105
  113
  123
  132
  142
  152
  159
  170
  182
  194
  207
  220
  233
  247
  262
  277
  293
  310
  327
  346
  365
  385
  405
  427
  450
  474
Maintenance CAPEX, $m
  -11
  -12
  -14
  -15
  -16
  -18
  -19
  -21
  -22
  -24
  -26
  -27
  -29
  -31
  -33
  -35
  -37
  -40
  -42
  -44
  -47
  -50
  -52
  -55
  -58
  -62
  -65
  -68
  -72
  -76
New CAPEX, $m
  -15
  -16
  -17
  -17
  -18
  -19
  -19
  -20
  -21
  -22
  -23
  -24
  -25
  -26
  -27
  -28
  -29
  -30
  -31
  -33
  -34
  -36
  -37
  -39
  -41
  -43
  -45
  -47
  -49
  -51
Cash from investing activities, $m
  -26
  -28
  -31
  -32
  -34
  -37
  -38
  -41
  -43
  -46
  -49
  -51
  -54
  -57
  -60
  -63
  -66
  -70
  -73
  -77
  -81
  -86
  -89
  -94
  -99
  -105
  -110
  -115
  -121
  -127
Free cash flow, $m
  47
  52
  58
  64
  70
  77
  84
  91
  99
  107
  111
  119
  128
  137
  147
  157
  167
  178
  189
  200
  212
  225
  238
  251
  266
  280
  296
  312
  329
  347
Issuance/(repayment) of debt, $m
  6
  6
  7
  7
  7
  8
  8
  8
  9
  9
  9
  10
  10
  10
  11
  11
  12
  12
  13
  13
  14
  14
  15
  16
  17
  17
  18
  19
  20
  21
Issuance/(repurchase) of shares, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  6
  6
  7
  7
  7
  8
  8
  8
  9
  9
  9
  10
  10
  10
  11
  11
  12
  12
  13
  13
  14
  14
  15
  16
  17
  17
  18
  19
  20
  21
Total cash flow (excl. dividends), $m
  53
  58
  65
  71
  78
  85
  92
  99
  107
  116
  120
  129
  138
  148
  158
  168
  179
  190
  201
  214
  226
  239
  253
  267
  282
  298
  314
  331
  349
  367
Retained Cash Flow (-), $m
  -41
  -43
  -45
  -47
  -49
  -51
  -53
  -55
  -57
  -59
  -62
  -64
  -67
  -69
  -72
  -75
  -78
  -82
  -85
  -89
  -93
  -97
  -101
  -106
  -111
  -116
  -121
  -127
  -132
  -139
Prev. year cash balance distribution, $m
  172
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  184
  15
  20
  24
  29
  34
  39
  44
  50
  56
  58
  65
  71
  78
  85
  93
  100
  108
  116
  125
  133
  142
  152
  162
  172
  182
  193
  204
  216
  229
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  176
  14
  17
  20
  22
  24
  26
  28
  29
  29
  28
  28
  27
  26
  25
  24
  22
  20
  18
  16
  14
  12
  10
  8
  7
  5
  4
  3
  2
  2
Current shareholders' claim on cash, %
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Neogen Corporation develops, manufactures and markets a range of products and services dedicated to food and animal safety. The Company operates through two segments: Food Safety and Animal Safety. The Food Safety segment produces and markets diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. The Animal Safety segment is primarily engaged in the production and marketing of products dedicated to animal health, including a range of consumable products marketed to veterinarians and animal health product distributors. The Animal Safety segment also provides genetic identification services. Additionally, the Animal Safety segment produces and markets rodenticides, disinfectants and insecticides to assist in the control of rodents and disease in and around agricultural, food production and other facilities.

FINANCIAL RATIOS  of  Neogen (NEOG)

Valuation Ratios
P/E Ratio 54.8
Price to Sales 6.7
Price to Book 5.1
Price to Tangible Book
Price to Cash Flow 40.2
Price to Free Cash Flow 53.6
Growth Rates
Sales Growth Rate 12.8%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 7.1%
Cap. Spend. - 3 Yr. Gr. Rate 4.6%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets 9%
Ret/ On Assets - 3 Yr. Avg. 9%
Return On Total Capital 10%
Ret/ On T. Cap. - 3 Yr. Avg. 10.1%
Return On Equity 10%
Return On Equity - 3 Yr. Avg. 10.1%
Asset Turnover 0.7
Profitability Ratios
Gross Margin 47.5%
Gross Margin - 3 Yr. Avg. 48.2%
EBITDA Margin 22.7%
EBITDA Margin - 3 Yr. Avg. 22.1%
Operating Margin 18%
Oper. Margin - 3 Yr. Avg. 18%
Pre-Tax Margin 18.5%
Pre-Tax Margin - 3 Yr. Avg. 18.1%
Net Profit Margin 12.2%
Net Profit Margin - 3 Yr. Avg. 11.9%
Effective Tax Rate 34.3%
Eff/ Tax Rate - 3 Yr. Avg. 34.3%
Payout Ratio 0%

NEOG stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the NEOG stock intrinsic value calculation we used $402.252 million for the last fiscal year's total revenue generated by Neogen. The default revenue input number comes from 0001 income statement of Neogen. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our NEOG stock valuation model: a) initial revenue growth rate of 10.6% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for NEOG is calculated based on our internal credit rating of Neogen, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Neogen.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of NEOG stock the variable cost ratio is equal to 82.1%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for NEOG stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Neogen.

Corporate tax rate of 27% is the nominal tax rate for Neogen. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the NEOG stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for NEOG are equal to 35.5%.

Life of production assets of 12.8 years is the average useful life of capital assets used in Neogen operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for NEOG is equal to 31.4%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $560.175 million for Neogen - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 51.757 million for Neogen is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Neogen at the current share price and the inputted number of shares is $3.3 billion.

RELATED COMPANIES Price Int.Val. Rating
IDXX IDEXX Laborato 200.57 85.24  str.sell
TMO Thermo Fisher 237.69 199.97  hold
BIO Bio-Rad Labora 273.22 323.94  hold
CRL Charles River 130.58 204.43  str.buy
DHR Danaher 101.65 86.30  hold
VIVO Meridian Biosc 19.41 14.33  hold
MMM 3M 204.91 232.48  hold
OSUR OraSure Techno 13.10 12.97  sell

COMPANY NEWS

▶ Neogen Board approves stock buyback   [Oct-10-18 09:45AM  PR Newswire]
▶ Weekly CEO Buys Highlight   [Oct-01-18 11:31AM  GuruFocus.com]
▶ Neogen: Fiscal 1Q Earnings Snapshot   [08:57AM  Associated Press]
▶ Neogen reports first quarter results   [08:45AM  PR Newswire]
▶ Neogen acquires Livestock Genetic Services   [Sep-04-18 08:45AM  PR Newswire]
▶ Neogen acquires water microbiology testing technology   [Aug-01-18 08:45AM  PR Newswire]
▶ Neogen: Fiscal 4Q Earnings Snapshot   [Jul-17-18 09:08AM  Associated Press]
▶ Neogen reports fiscal 2018 results   [08:45AM  PR Newswire]
▶ Earnings Preview For Neogen   [Jul-16-18 05:34PM  Benzinga]
▶ Breakout Watch: This Medical Stock Is Outperforming 99% Of All Stocks   [Apr-26-18 04:42PM  Investor's Business Daily]
▶ Neogen names Donofrio VP of Food Safety R&D   [Apr-19-18 08:45AM  PR Newswire]
▶ Is Neogen Corporations (NASDAQ:NEOG) Liquidity Good Enough?   [Apr-10-18 02:31PM  Simply Wall St.]
▶ Neogen chairman to gift stock   [Apr-06-18 11:30AM  PR Newswire]
▶ Neogen beats 3Q profit forecasts   [Mar-22-18 09:08AM  Associated Press]
▶ Neogen reports third quarter results   [08:45AM  PR Newswire]
▶ 5 Top Earnings Growth Stocks to Buy in February   [Feb-02-18 08:57AM  Zacks]
▶ Neogen releases easiest dairy antibiotic tests   [Feb-01-18 08:45AM  PR Newswire]
▶ Neogen tops 2Q profit forecasts   [Jan-03-18 09:03AM  Associated Press]
▶ Neogen shares begin post-split trading   [Jan-02-18 08:45AM  PR Newswire]
▶ Neogen announces 4-for-3 stock split   [08:45AM  PR Newswire]
▶ Neogen announces Bradley retirement   [Dec-06-17 08:45AM  PR Newswire]
▶ Stocks With Rising Composite Ratings: Neogen   [Nov-10-17 03:00AM  Investor's Business Daily]
▶ ETFs with exposure to Neogen Corp. : November 6, 2017   [Nov-06-17 12:08PM  Capital Cube]
▶ Neogen announces science change   [Oct-31-17 09:15AM  PR Newswire]
▶ ETFs with exposure to Neogen Corp. : October 26, 2017   [Oct-26-17 10:41AM  Capital Cube]
▶ ETFs with exposure to Neogen Corp. : October 16, 2017   [Oct-16-17 09:57AM  Capital Cube]
▶ ETFs with exposure to Neogen Corp. : October 4, 2017   [Oct-04-17 10:52AM  Capital Cube]
▶ Neogen Earns Membership In 95-Plus Composite Rating Club   [Sep-27-17 03:00AM  Investor's Business Daily]
▶ ETFs with exposure to Neogen Corp. : September 22, 2017   [Sep-22-17 11:15AM  Capital Cube]
▶ Neogen announces management change   [08:00AM  PR Newswire]
▶ Neogen beats Street 1Q forecasts   [Sep-19-17 11:56PM  Associated Press]
▶ Neogen reports 21% net income increase   [08:45AM  PR Newswire]
▶ ETFs with exposure to Neogen Corp. : August 15, 2017   [Aug-15-17 04:40PM  Capital Cube]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.